DNA Repair data presented at American Academy of Dermatology Meeting
First results of afamelanotide in xeroderma pigmentosum C (XPC) presented to Photodermatology...
Read MoreStatement on Silicon Valley Bank (SVB)
Melbourne, Australia, 13 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreNews Communiqué I - Maestro Jaap van Zweden
Introducing CLINUVEL Intriguing Personality (CUVIP), Maestro Jaap van Zweden.
Read MoreCommercial Update SCENESSE®
CLINUVEL today published its 2022 status report on the commercial distribution of...
Read MoreRelief from Quarterly Reporting
Melbourne, Australia, 2 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreCLINUVEL launches CYACÊLLE, Next Generation Solar Care
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreCYACÊLLE Polychromatic Solar Care – λ3
Melbourne, Australia, 01 March 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreProposed issue of Securities
Melbourne, Australia, 28 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreGlobal SCENESSE® demand drives increased CLINUVEL revenues, earnings
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreAppendix 4D Half Yearly Report
Melbourne, Australia, 24 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MorePRÉNUMBRA® Formulation Completed For Clinical Trial Use
CLINUVEL today announced the completion of manufacture of the first cGMP batch...
Read MoreChair's Letter
Melbourne, Australia, 09 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreAfamelanotide Significantly Reduces UV Skin Damage in a Healthy Population - Technical Note
Melbourne, Australia, 02 February 2023 ASX: CUV Börse Frankfurt: UR9 ADR Level...
Read MoreCLINUVEL Drug Significantly Reduces Critical UV Skin Damage in Fair-Skinned Individuals
Results released today from a clinical study have shown that the drug...
Read More